Jatcorp（JAT）株式概要ジャトコープ・リミテッドはオーストラリア、中国、ニュージーランドで乳製品、植物由来の健康食品、サプリメント製品の製造・販売を行っている。 詳細JAT ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析Australian市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( A$14M )過去1年間で株主の希薄化は大幅に進んだ すべてのリスクチェックを見るJAT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.1343.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18m67m2016201920222025202620282031Revenue AU$57.9mEarnings AU$2.5mAdvancedSet Fair ValueView all narrativesJatcorp Limited 競合他社NTAW HoldingsSymbol: ASX:NTDMarket cap: AU$35.2mBapcorSymbol: ASX:BAPMarket cap: AU$296.0mCity Chic CollectiveSymbol: ASX:CCXMarket cap: AU$15.4mSupply NetworkSymbol: ASX:SNLMarket cap: AU$1.4b価格と性能株価の高値、安値、推移の概要Jatcorp過去の株価現在の株価AU$0.1352週高値AU$0.4652週安値AU$0.10ベータ0.621ヶ月の変化0%3ヶ月変化-3.85%1年変化-72.83%3年間の変化-62.12%5年間の変化-80.16%IPOからの変化-99.23%最新ニュースNew Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$15.7m market cap, or US$11.4m).New Risk • Apr 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$10.00m).Reported Earnings • Mar 04First half 2026 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2025)First half 2026 results: AU$0.022 loss per share (improved from AU$0.034 loss in 1H 2025). Revenue: AU$23.0m (up 36% from 1H 2025). Net loss: AU$1.82m (loss narrowed 36% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.9m (US$9.15m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$12.9m market cap, or US$9.15m). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change).New Risk • Jan 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.0m market cap, or US$12.0m).お知らせ • Jan 16Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million.Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,088,887 Price\Range: AUD 0.15 Discount Per Security: AUD 0.00225 Transaction Features: Rights Offering最新情報をもっと見るRecent updatesNew Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$15.7m market cap, or US$11.4m).New Risk • Apr 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$10.00m).Reported Earnings • Mar 04First half 2026 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2025)First half 2026 results: AU$0.022 loss per share (improved from AU$0.034 loss in 1H 2025). Revenue: AU$23.0m (up 36% from 1H 2025). Net loss: AU$1.82m (loss narrowed 36% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.9m (US$9.15m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$12.9m market cap, or US$9.15m). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change).New Risk • Jan 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.0m market cap, or US$12.0m).お知らせ • Jan 16Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million.Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,088,887 Price\Range: AUD 0.15 Discount Per Security: AUD 0.00225 Transaction Features: Rights OfferingBuy Or Sell Opportunity • Dec 18Now 41% overvaluedOver the last 90 days, the stock has fallen 44% to AU$0.14. The fair value is estimated to be AU$0.099, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 16% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AU$9.69m market cap, or US$6.41m). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change).分析記事 • Dec 10Some Shareholders Feeling Restless Over Jatcorp Limited's (ASX:JAT) P/S RatioThere wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.4x is worth a...お知らせ • Dec 10Jatcorp Limited has filed a Follow-on Equity Offering in the amount of AUD 4.213333 million.Jatcorp Limited has filed a Follow-on Equity Offering in the amount of AUD 4.213333 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,088,887 Price\Range: AUD 0.15 Discount Per Security: AUD 0.00225 Transaction Features: Rights Offeringお知らせ • Oct 28Jatcorp Limited, Annual General Meeting, Nov 26, 2025Jatcorp Limited, Annual General Meeting, Nov 26, 2025. Location: suite 206, 5 rider boulevard, rhodes nsw 2138, AustraliaNew Risk • Oct 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.分析記事 • Sep 01Some Confidence Is Lacking In Jatcorp Limited (ASX:JAT) As Shares Slide 29%To the annoyance of some shareholders, Jatcorp Limited ( ASX:JAT ) shares are down a considerable 29% in the last...Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.03 loss per share (vs AU$0.028 profit in FY 2024)Full year 2025 results: AU$0.03 loss per share (down from AU$0.028 profit in FY 2024). Revenue: AU$34.8m (down 34% from FY 2024). Net loss: AU$2.47m (down 207% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.分析記事 • Jul 12Jatcorp Limited (ASX:JAT) Shares May Have Slumped 32% But Getting In Cheap Is Still UnlikelyThe Jatcorp Limited ( ASX:JAT ) share price has fared very poorly over the last month, falling by a substantial 32...お知らせ • Jul 11Jatcorp Limited Provides Unaudited Earnings Guidance for the Financial Year Ended 30 June 2025Jatcorp Limited provided unaudited earnings guidance for the financial year ended 30 June 2025. For the year, the company expects to report a net loss after tax in the range of $7.6 million to $8 million. This represents a further $1.5 million to $1.9 million(unaudited) of net loss in the second half of FY2025 as compared with $6.1 million (unaudited) of net loss reported for the first half of FY2025, and a material decline in financial performance compared to the Company's FY2024 audited result.分析記事 • May 10There's Reason For Concern Over Jatcorp Limited's (ASX:JAT) Massive 26% Price JumpJatcorp Limited ( ASX:JAT ) shareholders have had their patience rewarded with a 26% share price jump in the last...分析記事 • Mar 21Risks Still Elevated At These Prices As Jatcorp Limited (ASX:JAT) Shares Dive 28%Jatcorp Limited ( ASX:JAT ) shareholders won't be pleased to see that the share price has had a very rough month...お知らせ • Mar 14Jatcorp Limited Appoints Dr Xinpeng (Sean) Li as an Executive DirectorThe Board of Jatcorp announced the appointment of Dr Xinpeng (Sean) Li as an Executive Director. Sean has extensive work experience in Technical Research, Project Management, Business Development, Data Analysis, Budget Management, contract negotiation and drafting, Investment Management, Enterprise Acquisitions and Integration. He has obtained a Batchelor of Chemical Engineering (Norwest University), a Masters in Mechanical Engineering (UNSW) and a PhD in Chemistry (UNSW).Reported Earnings • Feb 28First half 2025 earnings released: AU$0.034 loss per share (vs AU$0.001 loss in 1H 2024)First half 2025 results: AU$0.034 loss per share (further deteriorated from AU$0.001 loss in 1H 2024). Revenue: AU$17.0m (down 61% from 1H 2024). Net loss: AU$2.83m (loss widened 218% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$38.7m market cap, or US$24.2m).分析記事 • Dec 15Not Many Are Piling Into Jatcorp Limited (ASX:JAT) Stock Yet As It Plummets 26%Unfortunately for some shareholders, the Jatcorp Limited ( ASX:JAT ) share price has dived 26% in the last thirty days...お知らせ • Nov 22Jatcorp Limited Announces Resignation of Mr. Jack Wang as Managing Director and DirectorJatcorp Limited (JAT) announced that Mr. Jack Wang has decided to resign as Managing Director and a director of JAT and all subsidiaries for personal reasons. The resignation is effective immediately. Mr. Wang remains as the largest shareholder of JAT. The company's operations will continue as usual under the leadership of the CEO, Mr. Sunny Liang, who will work closely with the Board to ensure ongoing stability and growth.分析記事 • Oct 27Jatcorp Limited (ASX:JAT) Might Not Be As Mispriced As It Looks After Plunging 25%Jatcorp Limited ( ASX:JAT ) shareholders that were waiting for something to happen have been dealt a blow with a 25...お知らせ • Oct 25Jatcorp Limited, Annual General Meeting, Nov 25, 2024Jatcorp Limited, Annual General Meeting, Nov 25, 2024. Location: 502/2 bligh street sydney nsw 2000, sydney AustraliaRecent Insider Transactions • Sep 15CEO & Executive Director recently bought AU$50k worth of stockOn the 13th of September, Jian Liang bought around 75k shares on-market at roughly AU$0.67 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Jian's only on-market trade for the last 12 months.Reported Earnings • Aug 31Full year 2024 earnings released: EPS: AU$0.028 (vs AU$0.028 loss in FY 2023)Full year 2024 results: EPS: AU$0.028 (up from AU$0.028 loss in FY 2023). Revenue: AU$52.5m (down 8.6% from FY 2023). Net income: AU$2.30m (up AU$4.61m from FY 2023). Profit margin: 4.4% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$50.0m market cap, or US$33.3m).分析記事 • Jun 16We Think Jatcorp (ASX:JAT) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Apr 24Market Still Lacking Some Conviction On Jatcorp Limited (ASX:JAT)There wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.3x is worth a...Reported Earnings • Feb 28First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.028 loss in 1H 2023)First half 2024 results: AU$0.001 loss per share (improved from AU$0.028 loss in 1H 2023). Revenue: AU$44.0m (up 178% from 1H 2023). Net loss: AU$889.8k (loss narrowed 61% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Feb 27Jatcorp Limited (ASX:JAT) acquired additional 30% stake in Australian Natural Milk Association Pty. Ltd.Jatcorp Limited (ASX:JAT) acquired additional 30% stake in Australian Natural Milk Association Pty. Ltd. in November, 2023.Jatcorp Limited (ASX:JAT) completed the acquisition of additional 30% stake in Australian Natural Milk Association Pty. Ltd. in November, 2023.お知らせ • Jan 08Jatcorp Limited Announces CEO ChangesThe Board of Jatcorp Limited announced to appoint Mr. Sunny Jianxin Liang as the CEO of Jatcorp. Sunny is a highly experienced senior business leader with over 13 years of experience within the export industry including infant formula, health supplements, skin care and personal care categories. Prior to this appointment, Sunny was COO and executive director of Jatcorp, where he was responsible for leading the business development and sales function. Termination Notice by CEO 3 months. Commencement Date is January 8, 2024. Jack Wang, who has served as Managing Director since September 2022, will remain in this role, and will focus on corporate strategic development including ESG, Investor relations, etc. and the Board management.分析記事 • Dec 18Jatcorp Limited's (ASX:JAT) Business Is Trailing The Industry But Its Shares Aren'tThere wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.4x is worth a...お知らせ • Nov 20Jatcorp Limited Appoints Kieran Pryke as Independent Director, Effective November 20, 2023Jatcorp Limited (JAT) has appointed Kieran Pryke as an Independent Director effective November 20, 2023. Kieran holds and has held significant executive and non-executive roles as a Director and Chief Financial Officer over a range of companies, and is currently a Director of Boom Logistics Limited, GFM Investment Management Limited, Aura Medical Group Pty Limited, Ozharvest Limited, and Bisley & Company Pty Limited. He brings to the Board extensive expertise in financing, structuring and strategy, and is a CPA Australia Fellow and member of AICD.Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.028 loss per share (vs AU$0.089 loss in FY 2022)Full year 2023 results: AU$0.028 loss per share (improved from AU$0.089 loss in FY 2022). Revenue: AU$57.4m (up 68% from FY 2022). Net loss: AU$2.31m (loss narrowed 59% from FY 2022). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.分析記事 • Sep 21Does Jatcorp (ASX:JATDD) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Sep 14Jatcorp Limited, Annual General Meeting, Nov 28, 2023Jatcorp Limited, Annual General Meeting, Nov 28, 2023, at 15:00 AUS Eastern Standard Time.Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.001 loss per share (improved from AU$0.004 loss in FY 2022). Revenue: AU$57.4m (up 52% from FY 2022). Net loss: AU$2.31m (loss narrowed 67% from FY 2022). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (AU$27.5m market cap, or US$17.8m).New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$25.0m market cap, or US$16.9m).分析記事 • Jun 21Does Jatcorp (ASX:JAT) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • May 18Jatcorp Limited Receives a Notice from Gold Brick Capital Pty LtdOn May 16, 2023, Jatcorp Limited announced that, it received a notice from Gold Brick Capital Pty Ltd to move resolutions at a general meeting to remove LNP Audit + Assurance as auditor of the Company and RSM Australia Pty Ltd be appointed as new auditor of the Company. Further, for the purposes of s328B(1) of the Corporations Act Gold Brick Capital Pty Ltd nominate RSM Australia Pty Ltd as auditor of the Company. In Addition, the Company stated that General Meetings of shareholders of will be held on June 14, 2023.分析記事 • Apr 18There's Reason For Concern Over Jatcorp Limited's (ASX:JAT) PriceThere wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.8x is worth a...Recent Insider Transactions • Mar 14MD & Executive Director recently bought AU$130k worth of stockOn the 8th of March, Zhan Wang bought around 10m shares on-market at roughly AU$0.013 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Zhan's only on-market trade for the last 12 months.Reported Earnings • Mar 03First half 2023 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2022)First half 2023 results: AU$0.001 loss per share (improved from AU$0.002 loss in 1H 2022). Revenue: AU$15.9m (down 1.2% from 1H 2022). Net loss: AU$2.31m (loss narrowed 28% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Jan 31Jatcorp Limited Announces Changes in DirectorateJatcorp Limited (JAT) is pleased to advise the appointment of Mr. Sunny Jian Xin Liang as COO and Executive Director, effective immediate. Mr. Liang has more than 10 years' experience in the export industry including infant formula, health supplements, skin care and personal care categories. Mr. Liang was previously a senior business development director for a major export and E-Commerce company, where he led the company through a period of significant growth and contract wins, achieved brand expansion and market penetration for clients, and built to annual turnover of over $400 million. In that role he oversaw operations in Australia, China, Vietnam, and other Asia countries. Scott Zhang has resigned as Executive Director and Chief Operating Officer to pursue alternative opportunities.お知らせ • Jan 10Jatcorp Limited Announces CEO Position UpdateJatcorp Limited (JAT) refers to its announcement dated 13 October 2022 whereby it advised that the CEO function for the Company would be carried out by the Company's Managing Director Mr. Jack Wang and Chief Operating Officer Mr. Scott Zhang until further notice. JAT has decided to make the announced change permanent, and accordingly on 24 December 2022 terminated Mr. Wilton Yao's employment. There are no changes to the previously announced terms of employment of Mr. Wang and Mr. Zhang including no changes to remuneration.分析記事 • Dec 21Health Check: How Prudently Does Jatcorp (ASX:JAT) Use Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Nov 28Jatcorp Limited Announces Retirement of Non-Executive Director, Bo Qiang (Charlie)The Board of Jatcorp Limited received notification from its Non-Executive Director Bo Qiang (Charlie) that he would retire at the AGM held on November 25, 2022 but not offer himself for re-election. Accordingly, the resolution to re-appoint him was withdrawn. Charlie joined the Company as Managing Director in June 2022. His strong background and good level experience in international trading business immediately enabled the Company to continue with its new strategic plan. During his tenure, he has provided valuable leadership to the executive and their teams. In September 2022, Charlie became one of the Non-Executive Directors of the Company and continued provide the Company with his support. Charlie has decided not to offer himself for election to spend more time and to be closer to his family. Charlie will continue to be a senior consultant of the Company.Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Chairman Dennis Shen is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Oct 14Jatcorp Limited Announces Management AdjustmentJatcorp Limited announced that as part of its ongoing commitment of continuously improving the Company's productivity and returns to stakeholders, the CEO function will be carried out by the Company's Managing Director Mr. Jack Wang and Chief Operating Officer Mr. Scott Zhang until further notice. Mr. Wilton Yao's position and activities within Jatcorp are under review and the Company expects to finalise this review soon.お知らせ • Sep 29+ 2 more updatesJatcorp Limited to Report Q1, 2023 Results on Oct 31, 2022Jatcorp Limited announced that they will report Q1, 2023 results on Oct 31, 2022お知らせ • Sep 09Jatcorp Limited Announces Executive ChangesJatcorp Limited announced that the Board has resolved to make the following management changes. Jack Zhang has been appointed as Managing Director. Mr. Wang's business footprint extends across China, Korea, Japan, and Southeast Asia, and he has rich experience in market development and sales. Mr. Wang is currently a Director of Pacific Healthy International Holdings Pty Ltd, and Pacific Healthy ANZ Pty Ltd, the leading distributors in the industries of dairy products, vitamin and cosmetics focusing on the Australia and Asian markets. Mr. Wang is the co-founder of HK Huibeijia Brand Manage Co., Ltd, which was established in 2014 and has more than 500 stores in mainland China. Scott Zhang has been appointed Executive Director and Chief Operating Officer. Charlie Qiang will revert to his original position as Non-Executive Director, and Dennis Shen remains as Chairman.お知らせ • Sep 07Jatcorp Limited Announces Cessation of Brett Crowley as Company SecretaryJatcorp Limited announced the cessation of Brett Crowley as Company Secretary.分析記事 • Sep 05Is Jatcorp (ASX:JAT) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.004 loss per share (vs AU$0.013 loss in FY 2021)Full year 2022 results: AU$0.004 loss per share (up from AU$0.013 loss in FY 2021). Revenue: AU$37.9m (up 81% from FY 2021). Net loss: AU$6.97m (loss narrowed 55% from FY 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.お知らせ • Sep 02Jatcorp Limited Announces Executive ChangesJatcorp Limited (JAT) announced that, following the results of General Meeting held on 1 September 2022, Brett Crowley and Mr. Binghui Gong (David) have ceased as directors. Mr. Zhiguo Zhang (Scott) has been appointed as a director. His details and experience are set out in the Notice of Meeting for today's meeting. Mr. Dennis (Peng) Shen has been elected as Chairman of the Board.お知らせ • Sep 01Jatcorp Limited Announces Board ChangesJatcorp Limited, at its AGM, held on 1 September 2022, approved the removal of BINGHUI GONG as director and the appointment of ZHIGUO ZHANG as the director of the company.お知らせ • Aug 18Jatcorp Limited Announces Resignation of Wilton Yao as Alternate Director for Brett CrowleyJatcorp Limited announced that Wilton Yao has resigned as an alternate director for Brett Crowley.お知らせ • Aug 01Jatcorp Limited Announces Removal of Brett Crowley and Binghui Gong as DirectorsJatcorp Limited, at its AGM, to be held on 1 September 2022, the shareholders will discuss the removal of Mr. Brett Crowley and Binghui Gong as directors.お知らせ • Jul 08Jatcorp Limited Announces Executive ChangesJatcorp Limited announced that it has appointed Li Yang as Chief Financial Officer replacing Jennifer Liu who has resigned. Li is a CPA with over 18 years' experience in senior finance management, most recently as Finance Manager for Industrial Food Services.お知らせ • Jul 04Jatcorp Limited Appoints Oliver Carton as Co-Company SecretaryJatcorp Limited (JAT) announced that it has appointed Oliver Carton as co-company secretary. Oliver is an experienced lawyer and company secretary, having provided outsourced company secretarial services for over 20 years. Prior to this he held roles as a director at KPMG, and a senior legal officer at ASIC.お知らせ • Jun 21+ 1 more updateJatcorp Limited Announces Executive ChangesJatcorp Limited announced Removal of Mr. Xin Sun. Appointment of Mr. Zhan Wang. Appointment of Mr. Peng Shen.お知らせ • Jun 17Jatcorp Limited Announces Board and Management ChangesJatcorp Limited announced that Charlie Qiang has been appointed the Managing Director of JAT. Charlie was appointed a director of JAT on 3 June 2022. He is a director and shareholder of JAT's fourth large shareholder, QHX Investments Pty Limited. Charlie has a strong background in rural business and trading with China, particularly in relation to the Shandong and Hebei provinces. Charlie already has this strong understanding of JAT's operations as a result of him having worked with JAT on new product development, sourcing of raw materials and commodity trading over a number of years. Further details regarding Charlie can be found in the ASX announcement dated 3 June 2022. Wilton Yao has resigned as a director and will continue to be responsible for the day-to-day operations of JAT including the creation of the cobranded products opportunity with Pinnacle. Given the expected increase in activity to be generated from those new opportunities, it has been decided that the other duties normally undertaken by Wilton will be assumed by the new Managing Director. JAT's Chairman, Brett Crowley, has appointed Wilton Yao as his alternate to act for him in the exercise all of the director's powers until further notice.お知らせ • Jun 03Jatcorp Limited Announces Board AppointmentsJatcorp Limited announced that it has significantly strengthened its board with the appointment of two new directors, Mr. Bo Qiang (Charlie) and Mr. Binghui Gong (David). Charlie is a director and shareholder of JAT's fourth largest shareholder, QHX Investments Pty Limited. Charlie has a strong background in rural business and trading with China, particularly in relation to the Shandong and Hebei provinces. In Australia, Charlie has had ownership of cattle stations in outback of SA and NT, exporting livestock and livestock products to Asia for a number of years. Since 2016, Charlie's properties have held the largest donkey herds in Australia and has developed Australiannutrition supplements based on Aboriginal bush tucker plants and traditional Chinese medicine. The properties produce are one of the largest live camel and wild buffalo suppliers. He has developed an import/export operation and participated developing local health product brand such as Australian Ejiao, as well as donkey milk and cheese, Camel milk powders and QG plum nectar juice. Charlie's Victorian properties grow and export Wagyu beef. Charlie's business activities including establishing an abattoir and food processing plant as well as the import and export of advanced bio and medical technology and products into China. David has had an extensive career in business management, especially marketing and sales, since 1995. He was Head of Sales of Guandong Apollo Group Co. Ltd. from 1995 to 2000. He is one of the founders and partners of By-Health Co., Ltd, one of China's largest science-based nutritional supplement suppliers. By-Health is listed on ChiNext of Shenzhen Stock Exchange (SZSE) with current market cap of the CNY equivalent of AUD7.8 billion. In the recent years, Mr. Gong is the overseas market investment, development and trading Consultant for By-Health and focused on Southeast Asian region, where he has many personal connections with major Chinese retail chains, Asian retail and investment groups. The appointment for Mr. Gong will greatly assist JAT to continue to develop specific market channels in China, particularly in the baby and mother store and health supplementary products channels. David will also be tasked with assisting JAT to improve its investment relations with potential investors Southeast Asian countries. David holds an MBA and business degree and is JAT's 23rd largest shareholder.お知らせ • May 12Jatcorp Limited Announces Resignation of DirectorJatcorp Limited announced that the company at General Meeting of Shareholders held on 20 June 2022 proposes the Removal of Mr. Wilton Yao and Mr. Xin Sun.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Xin Sun was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 01Jatcorp Limited announced that it expects to receive AUD 7.7 million in funding from Gold Brick Capital Pty Ltd, SBC Global InvestorsJatcorp Limited announced a private placement of 275,000,000 shares at a issue price of AUD 0.016 per share for gross proceeds of AUD 4,400,000 and secured convertible note facility for gross proceeds of AUD 3,300,000 for aggregate gross proceeds of AUD 7,700,000 on March 31, 2022. The transaction will include participation from SBC Global Investment Fund, a fund managed by SBC Global Investors for AUD 3,300,000, Gold Brick Capital Pty Ltd for AUD 2,000,000 and remaining AUD 2,200,000 from current shareholders and associates of the company. The Investor may convert the Notes at the Fixed Conversion Price or a 5% discount to the lowest VWAP in the 10 days preceding Conversion. The Company will issue to SBC Global Investment Fund a number of shares equal to 40% of the Funded Amount of the Notes divided by the price of the Concurrent Placement.分析記事 • Mar 21We Think Jatcorp (ASX:JAT) Has A Fair Chunk Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Mar 06Jatcorp Limited Announces RMIT Preliminary Research Report on JAT's Supplementary Food Formulas Effect on SARS-CoV-2 VariantsOn 6 September 2021, Jatcorp Limited announced that Royal Melbourne Institute of Technology (RMIT) had been commissioned to undertake a research project (Project) to undertake clinical trials to investigate the ability of JAT's supplementary food formulas, Jinvigorate Platinum and Moroka Platinum, to promote enhanced immune function and antiviral activity. Subsequently, RMIT conducted a preliminary scientific research study to determine potential antiviral properties of the milk molecules present in JAT's supplementary food formulas against SARS-CoV-2 variants. The first report (Report) from the Project has been provided by RMIT to JAT. The summary of the findings from the Report are set out below. The Report is in relation to the preliminary scientific research study based on in silico evidence only. The findings are very encouraging for immune support aspects of Jinvigorate Platinum and Moroka Platinum formulas. One of the conclusions is that the testing of the Jinvigorate Platinum and Moroka Platinum formulas ".suggest high binding effectiveness against the omicron variant, particularly for the lactoperoxidase enzyme product hypothiocyanite." The hypothesis of the Project's upcoming clinical trial is that on consuming JAT's LF-Ig formulas (Jinvigorate Platinum and Moroka Platinum), human subjects would exhibit improved immune function and responses to a model vaccine, and may be better protected against upper respiratory tract infections (such as Flu and Covid). The human subjects will be aged between 20 and 70 years of age and a total of 75 subjects will be screened/recruited. One of the hypotheses for the Report was that the application of molecular docking could be extended to elucidate key interactions between LF and the viral S protein of SARS-CoV-2. In the Report dated 3 March 2022, which is based on in silico evidence, RMIT stated: Well studied anti-microbial molecules (lactoferrin, lactoperoxidase and immunoglobulins) present in supplementary food formulas developed by JATCORP were studied by computational methods to determine their potential effectiveness against SARS-CoV-2 variants. The company employed molecular simulation methods to predict the binding of lactoferrin, hypothiocyanite (a product of lactoperoxidase), and prototypical bovine antibodies to the spike protein of the L strain, delta variant and omicron variant. All milk components studied are predicted to bind strongly to the SARS-CoV-2 spike protein and may disrupt virus-human interaction. Results suggest high binding effectiveness against the omicron variant, particularly for the lactoperoxidase enzyme product hypothiocyanite. This work is part of a multidisciplinary study including in vitro and in vivo experiments, conducted on a formula innovated by JATCORP containing components with antiviral properties, which will support and form the basis for upcoming clinical trials on human subjects. These preliminary studies highlight the potential for developing food-based products/dietary supplements for managing COVID-19 infection. While these findings are promising, well-designed clinical trials to test the predictions must be completed before making specific health claims. The effectiveness of milk products including these components in prevention, treatment or management of COVID-19 should be further examined by in vitro and in vivo studies. The next stage is for clinical trials on humans to be conducted by RMIT to evaluate whether, on consuming JAT's LF-Ig formulas (Jinvigorate Platinum and Moroka Platinum), the humans exhibit improved immune function and recovery times after contracting viruses and evaluate the protection against upper respiratory tract infections (such as Flu and Covid). This RMIT Report further reinforces the findings made previously by The University of Sydney. The basis of the JAT involvement in creating the co-branded CocoSoul Moroka products to be manufactured and marketed by Saputo was the ability of JAT to deliver the immune support products having the antiviral properties described in The University of Sydney research. JAT has been working with its co-branding partner and Saputo on the basis that the RMIT Report would support and extend the previous findings of The University of Sydney on JAT's immune support products. As a result of the findings in the RMIT Report, the CocoSoul Moroka products will be extended to include five drink products, being coconut milk with immune support (1L), coconut and oat milk with immune support (1L), coffee drink with immune support (250ml), matcha drink with immune support (250ml) and coconut and oat milk drink with immune support (250ml). These products will be released to the market by Saputo in late April/early May 2022.Reported Earnings • Mar 02First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.004 loss per share (down from AU$0.003 loss in 1H 2021). Revenue: AU$16.0m (up 19% from 1H 2021). Net loss: AU$3.23m (loss widened 7.3% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 03Jatcorp Limited Announces Resignation of Justyn Stedwell as Joint Company SecretaryJatcorp Limited announced that Justyn Stedwell has resigned as joint company secretary with immediate effect. Brett Crowley will continue as sole company secretary.分析記事 • Sep 08Is Jatcorp (ASX:JAT) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Sep 01Full year 2021 earnings released: AU$0.013 loss per share (vs AU$0.02 loss in FY 2020)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2021 results: Revenue: AU$21.0m (down 65% from FY 2020). Net loss: AU$15.3m (loss narrowed 13% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 23Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 6.195 million.Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 6.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 344,166,667 Price\Range: AUD 0.018 Transaction Features: Subsequent Direct Listingお知らせ • Jun 17Jatcorp Limited announced that it expects to receive AUD 6.195 million in fundingJatcorp Limited (ASX:JAT) announced a private placement of 344,166,667 shares at a price of AUD 0.018 per share for gross proceeds of AUD 6,195,000 on June 16, 2021. The transaction will include participation from sophisticated and professional investors including distributors and current shareholders. the transaction is expected to close on or around 18 June 2021.Reported Earnings • Mar 03First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020)The company reported a poor first half result with increased losses, weaker revenues and weaker control over costs. First half 2021 results: Revenue: AU$13.5m (down 56% from 1H 2020). Net loss: AU$3.01m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year and the company’s share price has also fallen by 46% per year.お知らせ • Jan 23Jatcorp Limited announced that it expects to receive AUD 2.827538 million in fundingJatcorp Limited (ASX:JAT) announced a private placement of 148,817,781 common shares at a price of AUD 0.019 per share for the gross proceeds of AUD 2,827,537.839 on January 22, 2021. The company will also issue one free attaching option for every two shares, equal to 74,408,891 options with a strike price of AUD 0.06 and an expiry date of January 29, 2023, subject to shareholder approval. The shares are expected to be issued on January 29, 2021. The transaction will include participation from Chairman, Brett Crowley for 10,000,000 shares at an expected price of AUD 0.02 per share for the gross proceeds of AUD 200,000, subject to shareholder approval.お知らせ • Dec 23Jatcorp Limited, Annual General Meeting, Jan 29, 2021Jatcorp Limited, Annual General Meeting, Jan 29, 2021, at 14:00 AUS Eastern Standard Time. Location: Level 5, 23-25 O'Connell Street Sydney New South Wales Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2020 together with the declaration of the Directors, the Directors' report, the remuneration report and the auditor's report; to discuss Adoption of Remuneration Report; to discuss Re-Election of Director Mr. Brett Crowley; to discuss buy back of shares; and to discuss Capacity to Issue Additional 10% of Securities.お知らせ • Dec 18Jatcorp Limited Enters into A 10 Year Sales Agreement with Nightingale PS Pty LtdJatcorp has entered into a 10 year sales agreement with Nightingale PS Pty Ltd. Under the agreement, Nightingale will use its networks to sell the current JAT products and all future products developed by JAT to its customers. Nightingale will receive a commission on revenues from sales by JAT. Nightingale will focus initially on the sale of products to specific Australian supermarket chains, followed by sales to pharmacies. The next step is intended to be the expansion of the JAT sales network to Nightingale's clients in the UK and to other markets outside China. The agreement can be terminated by either party for breach of the agreement which has not been remedied after 10 working days notice. There are no conditions precedent.分析記事 • Dec 17Is Jatcorp (ASX:JAT) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...お知らせ • Oct 06+ 1 more updateJatcorp Limited Signs a Distribution Agreement with HongKong Suning Appliance Resourcing LtdJatcorp Limited announced that the Company has received its first purchase order following its signing of a distribution agreement with HongKong Suning Appliance Resourcing Ltd. (Suning), based in Hong Kong on 30 September 2020. The agreement will see Suning distribute Australian products including JAT's in-house brands in mainland China on a non-exclusive basis. Suning is part of the Suning Holdings Group, which is one of the largest civilian-run enterprises in mainland China, and is primarily involved in the trading of FMCG products. This agreement aligns with JAT's strategic plan for China focusing on dealing with large state-owned or private companies, such as Suning. JAT sees dealing with larger enterprise counterparties as providing the Company with a much more stable and reliable distribution platform, helping to mitigate any potential changes in the Chinese trading environment. The current agreement has no conditions precedent and runs until 31 December 2020, with the parties planning based on initial success to sign a new annual agreement in January 2021. Under the terms of the agreement, Suning will place orders for products which JAT will deliver to China, Suning will pay the Chinese customs and other related charges, and Suning will make payment to JAT within 3 days of each batch of products arriving at their warehouse. Suning has made its first purchase order with an order value of AUD 127,000.お知らせ • Sep 22+ 2 more updatesJatcorp Limited Enters into Distribution Agreement with Shengding Pty LtdJatcorp Limited has entered into an agreement with Shengding Pty Limited which gives Shengding the exclusive right to distribute the Moroka formula into supermarkets throughout China. Shengding has in recent years successfully distributed many Australian products into Chinese supermarkets including the new concept retail stores. It is expected that Shengding will assist JAT to distribute lactoferrin range products into China's supermarket chains and new concept retail chains such as Hema Supermarket (owned by Alibaba Group) and 7Fresh (owned by JD Group). This is significant for JAT since most of JAT's lactoferrin products including Neurio range have predominantly been sold in the baby and mother stores. The relationship with Shengding it is expected to expand JAT's Chinese sales network into Chinese supermarket chains and the new concept chains being developed such as Hema and 7Fresh. Shengding will also assist JAT distribute the other JAT in-house products currently under development. The material terms of the agreement are as follows: The term is 24 months commencing 16 September 2020; Shengding has agreed to purchase 100,000 tins of products from JAT in the first 12 months of the agreement. This amounts to approximately AUD 1.1 million ex-warehouse in Shanghai; JAT can terminate the agreement if Shending fails to distribute the product or distributes the product outside China; there are no conditions precedent.株主還元JATAU Retail DistributorsAU 市場7D-13.8%1.0%1.7%1Y-72.8%-16.5%2.2%株主還元を見る業界別リターン: JAT過去 1 年間で-18.2 % の収益を上げたAustralian Retail Distributors業界を下回りました。リターン対市場: JATは、過去 1 年間で0 % のリターンを上げたAustralian市場を下回りました。価格変動Is JAT's price volatile compared to industry and market?JAT volatilityJAT Average Weekly Movement30.2%Retail Distributors Industry Average Movement5.7%Market Average Movement10.1%10% most volatile stocks in AU Market17.2%10% least volatile stocks in AU Market4.0%安定した株価: JATの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: JATの 週次ボラティリティ は、過去 1 年間で19%から30%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2006n/aSunny Liangjatcorp.comジャトコープ社は、オーストラリア、中国、ニュージーランドで、乳製品、植物由来の健康食品、サプリメント製品の製造・販売を行っている。同社は牛乳とヤギ乳をベースにした製品、クリームとスキムミルクパウダーを提供している。Jinvigorate、Neurio、iOne、Morokaのブランド名で製品を提供している。また、消費財の専門商社としても活動している。同社は小売およびeコマース・プラットフォームを通じて製品を販売している。旧社名はJatenergy Limitedで、2020年6月にJatcorp Limitedに社名変更した。ジャトコープ・リミテッドは2006年に設立され、オーストラリアのデリマットに本社を置く。もっと見るJatcorp Limited 基礎のまとめJatcorp の収益と売上を時価総額と比較するとどうか。JAT 基礎統計学時価総額AU$14.04m収益（TTM）-AU$1.46m売上高(TTM)AU$40.92m0.3xP/Sレシオ-9.6xPER（株価収益率JAT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計JAT 損益計算書（TTM）収益AU$40.92m売上原価AU$27.19m売上総利益AU$13.72mその他の費用AU$15.18m収益-AU$1.46m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.013グロス・マージン33.54%純利益率-3.56%有利子負債／自己資本比率67.2%JAT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 04:02終値2026/06/12 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jatcorp Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$15.7m market cap, or US$11.4m).
New Risk • Apr 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$10.00m).
Reported Earnings • Mar 04First half 2026 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2025)First half 2026 results: AU$0.022 loss per share (improved from AU$0.034 loss in 1H 2025). Revenue: AU$23.0m (up 36% from 1H 2025). Net loss: AU$1.82m (loss narrowed 36% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.9m (US$9.15m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$12.9m market cap, or US$9.15m). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change).
New Risk • Jan 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.0m market cap, or US$12.0m).
お知らせ • Jan 16Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million.Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,088,887 Price\Range: AUD 0.15 Discount Per Security: AUD 0.00225 Transaction Features: Rights Offering
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$15.7m market cap, or US$11.4m).
New Risk • Apr 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.0m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$14.0m market cap, or US$10.00m).
Reported Earnings • Mar 04First half 2026 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2025)First half 2026 results: AU$0.022 loss per share (improved from AU$0.034 loss in 1H 2025). Revenue: AU$23.0m (up 36% from 1H 2025). Net loss: AU$1.82m (loss narrowed 36% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
New Risk • Mar 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.9m (US$9.15m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Market cap is less than US$10m (AU$12.9m market cap, or US$9.15m). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change).
New Risk • Jan 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.0m market cap, or US$12.0m).
お知らせ • Jan 16Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million.Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 4.213333 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,088,887 Price\Range: AUD 0.15 Discount Per Security: AUD 0.00225 Transaction Features: Rights Offering
Buy Or Sell Opportunity • Dec 18Now 41% overvaluedOver the last 90 days, the stock has fallen 44% to AU$0.14. The fair value is estimated to be AU$0.099, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 16% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AU$9.69m market cap, or US$6.41m). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change).
分析記事 • Dec 10Some Shareholders Feeling Restless Over Jatcorp Limited's (ASX:JAT) P/S RatioThere wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.4x is worth a...
お知らせ • Dec 10Jatcorp Limited has filed a Follow-on Equity Offering in the amount of AUD 4.213333 million.Jatcorp Limited has filed a Follow-on Equity Offering in the amount of AUD 4.213333 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 28,088,887 Price\Range: AUD 0.15 Discount Per Security: AUD 0.00225 Transaction Features: Rights Offering
お知らせ • Oct 28Jatcorp Limited, Annual General Meeting, Nov 26, 2025Jatcorp Limited, Annual General Meeting, Nov 26, 2025. Location: suite 206, 5 rider boulevard, rhodes nsw 2138, Australia
New Risk • Oct 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
分析記事 • Sep 01Some Confidence Is Lacking In Jatcorp Limited (ASX:JAT) As Shares Slide 29%To the annoyance of some shareholders, Jatcorp Limited ( ASX:JAT ) shares are down a considerable 29% in the last...
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.03 loss per share (vs AU$0.028 profit in FY 2024)Full year 2025 results: AU$0.03 loss per share (down from AU$0.028 profit in FY 2024). Revenue: AU$34.8m (down 34% from FY 2024). Net loss: AU$2.47m (down 207% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
分析記事 • Jul 12Jatcorp Limited (ASX:JAT) Shares May Have Slumped 32% But Getting In Cheap Is Still UnlikelyThe Jatcorp Limited ( ASX:JAT ) share price has fared very poorly over the last month, falling by a substantial 32...
お知らせ • Jul 11Jatcorp Limited Provides Unaudited Earnings Guidance for the Financial Year Ended 30 June 2025Jatcorp Limited provided unaudited earnings guidance for the financial year ended 30 June 2025. For the year, the company expects to report a net loss after tax in the range of $7.6 million to $8 million. This represents a further $1.5 million to $1.9 million(unaudited) of net loss in the second half of FY2025 as compared with $6.1 million (unaudited) of net loss reported for the first half of FY2025, and a material decline in financial performance compared to the Company's FY2024 audited result.
分析記事 • May 10There's Reason For Concern Over Jatcorp Limited's (ASX:JAT) Massive 26% Price JumpJatcorp Limited ( ASX:JAT ) shareholders have had their patience rewarded with a 26% share price jump in the last...
分析記事 • Mar 21Risks Still Elevated At These Prices As Jatcorp Limited (ASX:JAT) Shares Dive 28%Jatcorp Limited ( ASX:JAT ) shareholders won't be pleased to see that the share price has had a very rough month...
お知らせ • Mar 14Jatcorp Limited Appoints Dr Xinpeng (Sean) Li as an Executive DirectorThe Board of Jatcorp announced the appointment of Dr Xinpeng (Sean) Li as an Executive Director. Sean has extensive work experience in Technical Research, Project Management, Business Development, Data Analysis, Budget Management, contract negotiation and drafting, Investment Management, Enterprise Acquisitions and Integration. He has obtained a Batchelor of Chemical Engineering (Norwest University), a Masters in Mechanical Engineering (UNSW) and a PhD in Chemistry (UNSW).
Reported Earnings • Feb 28First half 2025 earnings released: AU$0.034 loss per share (vs AU$0.001 loss in 1H 2024)First half 2025 results: AU$0.034 loss per share (further deteriorated from AU$0.001 loss in 1H 2024). Revenue: AU$17.0m (down 61% from 1H 2024). Net loss: AU$2.83m (loss widened 218% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$38.7m market cap, or US$24.2m).
分析記事 • Dec 15Not Many Are Piling Into Jatcorp Limited (ASX:JAT) Stock Yet As It Plummets 26%Unfortunately for some shareholders, the Jatcorp Limited ( ASX:JAT ) share price has dived 26% in the last thirty days...
お知らせ • Nov 22Jatcorp Limited Announces Resignation of Mr. Jack Wang as Managing Director and DirectorJatcorp Limited (JAT) announced that Mr. Jack Wang has decided to resign as Managing Director and a director of JAT and all subsidiaries for personal reasons. The resignation is effective immediately. Mr. Wang remains as the largest shareholder of JAT. The company's operations will continue as usual under the leadership of the CEO, Mr. Sunny Liang, who will work closely with the Board to ensure ongoing stability and growth.
分析記事 • Oct 27Jatcorp Limited (ASX:JAT) Might Not Be As Mispriced As It Looks After Plunging 25%Jatcorp Limited ( ASX:JAT ) shareholders that were waiting for something to happen have been dealt a blow with a 25...
お知らせ • Oct 25Jatcorp Limited, Annual General Meeting, Nov 25, 2024Jatcorp Limited, Annual General Meeting, Nov 25, 2024. Location: 502/2 bligh street sydney nsw 2000, sydney Australia
Recent Insider Transactions • Sep 15CEO & Executive Director recently bought AU$50k worth of stockOn the 13th of September, Jian Liang bought around 75k shares on-market at roughly AU$0.67 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Jian's only on-market trade for the last 12 months.
Reported Earnings • Aug 31Full year 2024 earnings released: EPS: AU$0.028 (vs AU$0.028 loss in FY 2023)Full year 2024 results: EPS: AU$0.028 (up from AU$0.028 loss in FY 2023). Revenue: AU$52.5m (down 8.6% from FY 2023). Net income: AU$2.30m (up AU$4.61m from FY 2023). Profit margin: 4.4% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$50.0m market cap, or US$33.3m).
分析記事 • Jun 16We Think Jatcorp (ASX:JAT) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Apr 24Market Still Lacking Some Conviction On Jatcorp Limited (ASX:JAT)There wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.3x is worth a...
Reported Earnings • Feb 28First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.028 loss in 1H 2023)First half 2024 results: AU$0.001 loss per share (improved from AU$0.028 loss in 1H 2023). Revenue: AU$44.0m (up 178% from 1H 2023). Net loss: AU$889.8k (loss narrowed 61% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Feb 27Jatcorp Limited (ASX:JAT) acquired additional 30% stake in Australian Natural Milk Association Pty. Ltd.Jatcorp Limited (ASX:JAT) acquired additional 30% stake in Australian Natural Milk Association Pty. Ltd. in November, 2023.Jatcorp Limited (ASX:JAT) completed the acquisition of additional 30% stake in Australian Natural Milk Association Pty. Ltd. in November, 2023.
お知らせ • Jan 08Jatcorp Limited Announces CEO ChangesThe Board of Jatcorp Limited announced to appoint Mr. Sunny Jianxin Liang as the CEO of Jatcorp. Sunny is a highly experienced senior business leader with over 13 years of experience within the export industry including infant formula, health supplements, skin care and personal care categories. Prior to this appointment, Sunny was COO and executive director of Jatcorp, where he was responsible for leading the business development and sales function. Termination Notice by CEO 3 months. Commencement Date is January 8, 2024. Jack Wang, who has served as Managing Director since September 2022, will remain in this role, and will focus on corporate strategic development including ESG, Investor relations, etc. and the Board management.
分析記事 • Dec 18Jatcorp Limited's (ASX:JAT) Business Is Trailing The Industry But Its Shares Aren'tThere wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.4x is worth a...
お知らせ • Nov 20Jatcorp Limited Appoints Kieran Pryke as Independent Director, Effective November 20, 2023Jatcorp Limited (JAT) has appointed Kieran Pryke as an Independent Director effective November 20, 2023. Kieran holds and has held significant executive and non-executive roles as a Director and Chief Financial Officer over a range of companies, and is currently a Director of Boom Logistics Limited, GFM Investment Management Limited, Aura Medical Group Pty Limited, Ozharvest Limited, and Bisley & Company Pty Limited. He brings to the Board extensive expertise in financing, structuring and strategy, and is a CPA Australia Fellow and member of AICD.
Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.028 loss per share (vs AU$0.089 loss in FY 2022)Full year 2023 results: AU$0.028 loss per share (improved from AU$0.089 loss in FY 2022). Revenue: AU$57.4m (up 68% from FY 2022). Net loss: AU$2.31m (loss narrowed 59% from FY 2022). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
分析記事 • Sep 21Does Jatcorp (ASX:JATDD) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Sep 14Jatcorp Limited, Annual General Meeting, Nov 28, 2023Jatcorp Limited, Annual General Meeting, Nov 28, 2023, at 15:00 AUS Eastern Standard Time.
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.001 loss per share (improved from AU$0.004 loss in FY 2022). Revenue: AU$57.4m (up 52% from FY 2022). Net loss: AU$2.31m (loss narrowed 67% from FY 2022). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (AU$27.5m market cap, or US$17.8m).
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$25.0m market cap, or US$16.9m).
分析記事 • Jun 21Does Jatcorp (ASX:JAT) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • May 18Jatcorp Limited Receives a Notice from Gold Brick Capital Pty LtdOn May 16, 2023, Jatcorp Limited announced that, it received a notice from Gold Brick Capital Pty Ltd to move resolutions at a general meeting to remove LNP Audit + Assurance as auditor of the Company and RSM Australia Pty Ltd be appointed as new auditor of the Company. Further, for the purposes of s328B(1) of the Corporations Act Gold Brick Capital Pty Ltd nominate RSM Australia Pty Ltd as auditor of the Company. In Addition, the Company stated that General Meetings of shareholders of will be held on June 14, 2023.
分析記事 • Apr 18There's Reason For Concern Over Jatcorp Limited's (ASX:JAT) PriceThere wouldn't be many who think Jatcorp Limited's ( ASX:JAT ) price-to-sales (or "P/S") ratio of 0.8x is worth a...
Recent Insider Transactions • Mar 14MD & Executive Director recently bought AU$130k worth of stockOn the 8th of March, Zhan Wang bought around 10m shares on-market at roughly AU$0.013 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Zhan's only on-market trade for the last 12 months.
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2022)First half 2023 results: AU$0.001 loss per share (improved from AU$0.002 loss in 1H 2022). Revenue: AU$15.9m (down 1.2% from 1H 2022). Net loss: AU$2.31m (loss narrowed 28% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Jan 31Jatcorp Limited Announces Changes in DirectorateJatcorp Limited (JAT) is pleased to advise the appointment of Mr. Sunny Jian Xin Liang as COO and Executive Director, effective immediate. Mr. Liang has more than 10 years' experience in the export industry including infant formula, health supplements, skin care and personal care categories. Mr. Liang was previously a senior business development director for a major export and E-Commerce company, where he led the company through a period of significant growth and contract wins, achieved brand expansion and market penetration for clients, and built to annual turnover of over $400 million. In that role he oversaw operations in Australia, China, Vietnam, and other Asia countries. Scott Zhang has resigned as Executive Director and Chief Operating Officer to pursue alternative opportunities.
お知らせ • Jan 10Jatcorp Limited Announces CEO Position UpdateJatcorp Limited (JAT) refers to its announcement dated 13 October 2022 whereby it advised that the CEO function for the Company would be carried out by the Company's Managing Director Mr. Jack Wang and Chief Operating Officer Mr. Scott Zhang until further notice. JAT has decided to make the announced change permanent, and accordingly on 24 December 2022 terminated Mr. Wilton Yao's employment. There are no changes to the previously announced terms of employment of Mr. Wang and Mr. Zhang including no changes to remuneration.
分析記事 • Dec 21Health Check: How Prudently Does Jatcorp (ASX:JAT) Use Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Nov 28Jatcorp Limited Announces Retirement of Non-Executive Director, Bo Qiang (Charlie)The Board of Jatcorp Limited received notification from its Non-Executive Director Bo Qiang (Charlie) that he would retire at the AGM held on November 25, 2022 but not offer himself for re-election. Accordingly, the resolution to re-appoint him was withdrawn. Charlie joined the Company as Managing Director in June 2022. His strong background and good level experience in international trading business immediately enabled the Company to continue with its new strategic plan. During his tenure, he has provided valuable leadership to the executive and their teams. In September 2022, Charlie became one of the Non-Executive Directors of the Company and continued provide the Company with his support. Charlie has decided not to offer himself for election to spend more time and to be closer to his family. Charlie will continue to be a senior consultant of the Company.
Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Chairman Dennis Shen is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Oct 14Jatcorp Limited Announces Management AdjustmentJatcorp Limited announced that as part of its ongoing commitment of continuously improving the Company's productivity and returns to stakeholders, the CEO function will be carried out by the Company's Managing Director Mr. Jack Wang and Chief Operating Officer Mr. Scott Zhang until further notice. Mr. Wilton Yao's position and activities within Jatcorp are under review and the Company expects to finalise this review soon.
お知らせ • Sep 29+ 2 more updatesJatcorp Limited to Report Q1, 2023 Results on Oct 31, 2022Jatcorp Limited announced that they will report Q1, 2023 results on Oct 31, 2022
お知らせ • Sep 09Jatcorp Limited Announces Executive ChangesJatcorp Limited announced that the Board has resolved to make the following management changes. Jack Zhang has been appointed as Managing Director. Mr. Wang's business footprint extends across China, Korea, Japan, and Southeast Asia, and he has rich experience in market development and sales. Mr. Wang is currently a Director of Pacific Healthy International Holdings Pty Ltd, and Pacific Healthy ANZ Pty Ltd, the leading distributors in the industries of dairy products, vitamin and cosmetics focusing on the Australia and Asian markets. Mr. Wang is the co-founder of HK Huibeijia Brand Manage Co., Ltd, which was established in 2014 and has more than 500 stores in mainland China. Scott Zhang has been appointed Executive Director and Chief Operating Officer. Charlie Qiang will revert to his original position as Non-Executive Director, and Dennis Shen remains as Chairman.
お知らせ • Sep 07Jatcorp Limited Announces Cessation of Brett Crowley as Company SecretaryJatcorp Limited announced the cessation of Brett Crowley as Company Secretary.
分析記事 • Sep 05Is Jatcorp (ASX:JAT) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.004 loss per share (vs AU$0.013 loss in FY 2021)Full year 2022 results: AU$0.004 loss per share (up from AU$0.013 loss in FY 2021). Revenue: AU$37.9m (up 81% from FY 2021). Net loss: AU$6.97m (loss narrowed 55% from FY 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
お知らせ • Sep 02Jatcorp Limited Announces Executive ChangesJatcorp Limited (JAT) announced that, following the results of General Meeting held on 1 September 2022, Brett Crowley and Mr. Binghui Gong (David) have ceased as directors. Mr. Zhiguo Zhang (Scott) has been appointed as a director. His details and experience are set out in the Notice of Meeting for today's meeting. Mr. Dennis (Peng) Shen has been elected as Chairman of the Board.
お知らせ • Sep 01Jatcorp Limited Announces Board ChangesJatcorp Limited, at its AGM, held on 1 September 2022, approved the removal of BINGHUI GONG as director and the appointment of ZHIGUO ZHANG as the director of the company.
お知らせ • Aug 18Jatcorp Limited Announces Resignation of Wilton Yao as Alternate Director for Brett CrowleyJatcorp Limited announced that Wilton Yao has resigned as an alternate director for Brett Crowley.
お知らせ • Aug 01Jatcorp Limited Announces Removal of Brett Crowley and Binghui Gong as DirectorsJatcorp Limited, at its AGM, to be held on 1 September 2022, the shareholders will discuss the removal of Mr. Brett Crowley and Binghui Gong as directors.
お知らせ • Jul 08Jatcorp Limited Announces Executive ChangesJatcorp Limited announced that it has appointed Li Yang as Chief Financial Officer replacing Jennifer Liu who has resigned. Li is a CPA with over 18 years' experience in senior finance management, most recently as Finance Manager for Industrial Food Services.
お知らせ • Jul 04Jatcorp Limited Appoints Oliver Carton as Co-Company SecretaryJatcorp Limited (JAT) announced that it has appointed Oliver Carton as co-company secretary. Oliver is an experienced lawyer and company secretary, having provided outsourced company secretarial services for over 20 years. Prior to this he held roles as a director at KPMG, and a senior legal officer at ASIC.
お知らせ • Jun 21+ 1 more updateJatcorp Limited Announces Executive ChangesJatcorp Limited announced Removal of Mr. Xin Sun. Appointment of Mr. Zhan Wang. Appointment of Mr. Peng Shen.
お知らせ • Jun 17Jatcorp Limited Announces Board and Management ChangesJatcorp Limited announced that Charlie Qiang has been appointed the Managing Director of JAT. Charlie was appointed a director of JAT on 3 June 2022. He is a director and shareholder of JAT's fourth large shareholder, QHX Investments Pty Limited. Charlie has a strong background in rural business and trading with China, particularly in relation to the Shandong and Hebei provinces. Charlie already has this strong understanding of JAT's operations as a result of him having worked with JAT on new product development, sourcing of raw materials and commodity trading over a number of years. Further details regarding Charlie can be found in the ASX announcement dated 3 June 2022. Wilton Yao has resigned as a director and will continue to be responsible for the day-to-day operations of JAT including the creation of the cobranded products opportunity with Pinnacle. Given the expected increase in activity to be generated from those new opportunities, it has been decided that the other duties normally undertaken by Wilton will be assumed by the new Managing Director. JAT's Chairman, Brett Crowley, has appointed Wilton Yao as his alternate to act for him in the exercise all of the director's powers until further notice.
お知らせ • Jun 03Jatcorp Limited Announces Board AppointmentsJatcorp Limited announced that it has significantly strengthened its board with the appointment of two new directors, Mr. Bo Qiang (Charlie) and Mr. Binghui Gong (David). Charlie is a director and shareholder of JAT's fourth largest shareholder, QHX Investments Pty Limited. Charlie has a strong background in rural business and trading with China, particularly in relation to the Shandong and Hebei provinces. In Australia, Charlie has had ownership of cattle stations in outback of SA and NT, exporting livestock and livestock products to Asia for a number of years. Since 2016, Charlie's properties have held the largest donkey herds in Australia and has developed Australiannutrition supplements based on Aboriginal bush tucker plants and traditional Chinese medicine. The properties produce are one of the largest live camel and wild buffalo suppliers. He has developed an import/export operation and participated developing local health product brand such as Australian Ejiao, as well as donkey milk and cheese, Camel milk powders and QG plum nectar juice. Charlie's Victorian properties grow and export Wagyu beef. Charlie's business activities including establishing an abattoir and food processing plant as well as the import and export of advanced bio and medical technology and products into China. David has had an extensive career in business management, especially marketing and sales, since 1995. He was Head of Sales of Guandong Apollo Group Co. Ltd. from 1995 to 2000. He is one of the founders and partners of By-Health Co., Ltd, one of China's largest science-based nutritional supplement suppliers. By-Health is listed on ChiNext of Shenzhen Stock Exchange (SZSE) with current market cap of the CNY equivalent of AUD7.8 billion. In the recent years, Mr. Gong is the overseas market investment, development and trading Consultant for By-Health and focused on Southeast Asian region, where he has many personal connections with major Chinese retail chains, Asian retail and investment groups. The appointment for Mr. Gong will greatly assist JAT to continue to develop specific market channels in China, particularly in the baby and mother store and health supplementary products channels. David will also be tasked with assisting JAT to improve its investment relations with potential investors Southeast Asian countries. David holds an MBA and business degree and is JAT's 23rd largest shareholder.
お知らせ • May 12Jatcorp Limited Announces Resignation of DirectorJatcorp Limited announced that the company at General Meeting of Shareholders held on 20 June 2022 proposes the Removal of Mr. Wilton Yao and Mr. Xin Sun.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Xin Sun was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 01Jatcorp Limited announced that it expects to receive AUD 7.7 million in funding from Gold Brick Capital Pty Ltd, SBC Global InvestorsJatcorp Limited announced a private placement of 275,000,000 shares at a issue price of AUD 0.016 per share for gross proceeds of AUD 4,400,000 and secured convertible note facility for gross proceeds of AUD 3,300,000 for aggregate gross proceeds of AUD 7,700,000 on March 31, 2022. The transaction will include participation from SBC Global Investment Fund, a fund managed by SBC Global Investors for AUD 3,300,000, Gold Brick Capital Pty Ltd for AUD 2,000,000 and remaining AUD 2,200,000 from current shareholders and associates of the company. The Investor may convert the Notes at the Fixed Conversion Price or a 5% discount to the lowest VWAP in the 10 days preceding Conversion. The Company will issue to SBC Global Investment Fund a number of shares equal to 40% of the Funded Amount of the Notes divided by the price of the Concurrent Placement.
分析記事 • Mar 21We Think Jatcorp (ASX:JAT) Has A Fair Chunk Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Mar 06Jatcorp Limited Announces RMIT Preliminary Research Report on JAT's Supplementary Food Formulas Effect on SARS-CoV-2 VariantsOn 6 September 2021, Jatcorp Limited announced that Royal Melbourne Institute of Technology (RMIT) had been commissioned to undertake a research project (Project) to undertake clinical trials to investigate the ability of JAT's supplementary food formulas, Jinvigorate Platinum and Moroka Platinum, to promote enhanced immune function and antiviral activity. Subsequently, RMIT conducted a preliminary scientific research study to determine potential antiviral properties of the milk molecules present in JAT's supplementary food formulas against SARS-CoV-2 variants. The first report (Report) from the Project has been provided by RMIT to JAT. The summary of the findings from the Report are set out below. The Report is in relation to the preliminary scientific research study based on in silico evidence only. The findings are very encouraging for immune support aspects of Jinvigorate Platinum and Moroka Platinum formulas. One of the conclusions is that the testing of the Jinvigorate Platinum and Moroka Platinum formulas ".suggest high binding effectiveness against the omicron variant, particularly for the lactoperoxidase enzyme product hypothiocyanite." The hypothesis of the Project's upcoming clinical trial is that on consuming JAT's LF-Ig formulas (Jinvigorate Platinum and Moroka Platinum), human subjects would exhibit improved immune function and responses to a model vaccine, and may be better protected against upper respiratory tract infections (such as Flu and Covid). The human subjects will be aged between 20 and 70 years of age and a total of 75 subjects will be screened/recruited. One of the hypotheses for the Report was that the application of molecular docking could be extended to elucidate key interactions between LF and the viral S protein of SARS-CoV-2. In the Report dated 3 March 2022, which is based on in silico evidence, RMIT stated: Well studied anti-microbial molecules (lactoferrin, lactoperoxidase and immunoglobulins) present in supplementary food formulas developed by JATCORP were studied by computational methods to determine their potential effectiveness against SARS-CoV-2 variants. The company employed molecular simulation methods to predict the binding of lactoferrin, hypothiocyanite (a product of lactoperoxidase), and prototypical bovine antibodies to the spike protein of the L strain, delta variant and omicron variant. All milk components studied are predicted to bind strongly to the SARS-CoV-2 spike protein and may disrupt virus-human interaction. Results suggest high binding effectiveness against the omicron variant, particularly for the lactoperoxidase enzyme product hypothiocyanite. This work is part of a multidisciplinary study including in vitro and in vivo experiments, conducted on a formula innovated by JATCORP containing components with antiviral properties, which will support and form the basis for upcoming clinical trials on human subjects. These preliminary studies highlight the potential for developing food-based products/dietary supplements for managing COVID-19 infection. While these findings are promising, well-designed clinical trials to test the predictions must be completed before making specific health claims. The effectiveness of milk products including these components in prevention, treatment or management of COVID-19 should be further examined by in vitro and in vivo studies. The next stage is for clinical trials on humans to be conducted by RMIT to evaluate whether, on consuming JAT's LF-Ig formulas (Jinvigorate Platinum and Moroka Platinum), the humans exhibit improved immune function and recovery times after contracting viruses and evaluate the protection against upper respiratory tract infections (such as Flu and Covid). This RMIT Report further reinforces the findings made previously by The University of Sydney. The basis of the JAT involvement in creating the co-branded CocoSoul Moroka products to be manufactured and marketed by Saputo was the ability of JAT to deliver the immune support products having the antiviral properties described in The University of Sydney research. JAT has been working with its co-branding partner and Saputo on the basis that the RMIT Report would support and extend the previous findings of The University of Sydney on JAT's immune support products. As a result of the findings in the RMIT Report, the CocoSoul Moroka products will be extended to include five drink products, being coconut milk with immune support (1L), coconut and oat milk with immune support (1L), coffee drink with immune support (250ml), matcha drink with immune support (250ml) and coconut and oat milk drink with immune support (250ml). These products will be released to the market by Saputo in late April/early May 2022.
Reported Earnings • Mar 02First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.004 loss per share (down from AU$0.003 loss in 1H 2021). Revenue: AU$16.0m (up 19% from 1H 2021). Net loss: AU$3.23m (loss widened 7.3% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 03Jatcorp Limited Announces Resignation of Justyn Stedwell as Joint Company SecretaryJatcorp Limited announced that Justyn Stedwell has resigned as joint company secretary with immediate effect. Brett Crowley will continue as sole company secretary.
分析記事 • Sep 08Is Jatcorp (ASX:JAT) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Sep 01Full year 2021 earnings released: AU$0.013 loss per share (vs AU$0.02 loss in FY 2020)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2021 results: Revenue: AU$21.0m (down 65% from FY 2020). Net loss: AU$15.3m (loss narrowed 13% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 23Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 6.195 million.Jatcorp Limited has completed a Follow-on Equity Offering in the amount of AUD 6.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 344,166,667 Price\Range: AUD 0.018 Transaction Features: Subsequent Direct Listing
お知らせ • Jun 17Jatcorp Limited announced that it expects to receive AUD 6.195 million in fundingJatcorp Limited (ASX:JAT) announced a private placement of 344,166,667 shares at a price of AUD 0.018 per share for gross proceeds of AUD 6,195,000 on June 16, 2021. The transaction will include participation from sophisticated and professional investors including distributors and current shareholders. the transaction is expected to close on or around 18 June 2021.
Reported Earnings • Mar 03First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020)The company reported a poor first half result with increased losses, weaker revenues and weaker control over costs. First half 2021 results: Revenue: AU$13.5m (down 56% from 1H 2020). Net loss: AU$3.01m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year and the company’s share price has also fallen by 46% per year.
お知らせ • Jan 23Jatcorp Limited announced that it expects to receive AUD 2.827538 million in fundingJatcorp Limited (ASX:JAT) announced a private placement of 148,817,781 common shares at a price of AUD 0.019 per share for the gross proceeds of AUD 2,827,537.839 on January 22, 2021. The company will also issue one free attaching option for every two shares, equal to 74,408,891 options with a strike price of AUD 0.06 and an expiry date of January 29, 2023, subject to shareholder approval. The shares are expected to be issued on January 29, 2021. The transaction will include participation from Chairman, Brett Crowley for 10,000,000 shares at an expected price of AUD 0.02 per share for the gross proceeds of AUD 200,000, subject to shareholder approval.
お知らせ • Dec 23Jatcorp Limited, Annual General Meeting, Jan 29, 2021Jatcorp Limited, Annual General Meeting, Jan 29, 2021, at 14:00 AUS Eastern Standard Time. Location: Level 5, 23-25 O'Connell Street Sydney New South Wales Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2020 together with the declaration of the Directors, the Directors' report, the remuneration report and the auditor's report; to discuss Adoption of Remuneration Report; to discuss Re-Election of Director Mr. Brett Crowley; to discuss buy back of shares; and to discuss Capacity to Issue Additional 10% of Securities.
お知らせ • Dec 18Jatcorp Limited Enters into A 10 Year Sales Agreement with Nightingale PS Pty LtdJatcorp has entered into a 10 year sales agreement with Nightingale PS Pty Ltd. Under the agreement, Nightingale will use its networks to sell the current JAT products and all future products developed by JAT to its customers. Nightingale will receive a commission on revenues from sales by JAT. Nightingale will focus initially on the sale of products to specific Australian supermarket chains, followed by sales to pharmacies. The next step is intended to be the expansion of the JAT sales network to Nightingale's clients in the UK and to other markets outside China. The agreement can be terminated by either party for breach of the agreement which has not been remedied after 10 working days notice. There are no conditions precedent.
分析記事 • Dec 17Is Jatcorp (ASX:JAT) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
お知らせ • Oct 06+ 1 more updateJatcorp Limited Signs a Distribution Agreement with HongKong Suning Appliance Resourcing LtdJatcorp Limited announced that the Company has received its first purchase order following its signing of a distribution agreement with HongKong Suning Appliance Resourcing Ltd. (Suning), based in Hong Kong on 30 September 2020. The agreement will see Suning distribute Australian products including JAT's in-house brands in mainland China on a non-exclusive basis. Suning is part of the Suning Holdings Group, which is one of the largest civilian-run enterprises in mainland China, and is primarily involved in the trading of FMCG products. This agreement aligns with JAT's strategic plan for China focusing on dealing with large state-owned or private companies, such as Suning. JAT sees dealing with larger enterprise counterparties as providing the Company with a much more stable and reliable distribution platform, helping to mitigate any potential changes in the Chinese trading environment. The current agreement has no conditions precedent and runs until 31 December 2020, with the parties planning based on initial success to sign a new annual agreement in January 2021. Under the terms of the agreement, Suning will place orders for products which JAT will deliver to China, Suning will pay the Chinese customs and other related charges, and Suning will make payment to JAT within 3 days of each batch of products arriving at their warehouse. Suning has made its first purchase order with an order value of AUD 127,000.
お知らせ • Sep 22+ 2 more updatesJatcorp Limited Enters into Distribution Agreement with Shengding Pty LtdJatcorp Limited has entered into an agreement with Shengding Pty Limited which gives Shengding the exclusive right to distribute the Moroka formula into supermarkets throughout China. Shengding has in recent years successfully distributed many Australian products into Chinese supermarkets including the new concept retail stores. It is expected that Shengding will assist JAT to distribute lactoferrin range products into China's supermarket chains and new concept retail chains such as Hema Supermarket (owned by Alibaba Group) and 7Fresh (owned by JD Group). This is significant for JAT since most of JAT's lactoferrin products including Neurio range have predominantly been sold in the baby and mother stores. The relationship with Shengding it is expected to expand JAT's Chinese sales network into Chinese supermarket chains and the new concept chains being developed such as Hema and 7Fresh. Shengding will also assist JAT distribute the other JAT in-house products currently under development. The material terms of the agreement are as follows: The term is 24 months commencing 16 September 2020; Shengding has agreed to purchase 100,000 tins of products from JAT in the first 12 months of the agreement. This amounts to approximately AUD 1.1 million ex-warehouse in Shanghai; JAT can terminate the agreement if Shending fails to distribute the product or distributes the product outside China; there are no conditions precedent.
